BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6577782)

  • 1. Influence of gemfibrozil on high-density lipoproteins.
    Glueck C
    Am J Cardiol; 1983 Aug; 52(4):31B-34B. PubMed ID: 6577782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical results with gemfibrozil.
    Pickering JE
    Am J Cardiol; 1983 Aug; 52(4):39B-40B. PubMed ID: 6351579
    [No Abstract]   [Full Text] [Related]  

  • 3. Mechanism of action of gemfibrozil on lipoprotein metabolism.
    Saku K; Gartside PS; Hynd BA; Kashyap ML
    J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperlipoproteinemia, atherosclerosis and gemfibrozil.
    Nash DT
    Angiology; 1982 Sep; 33(9):594-602. PubMed ID: 6957155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
    Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
    J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
    Nye ER; Sutherland WH; Temple Wa
    N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats.
    Krause BR; Newton RS
    J Lipid Res; 1985 Aug; 26(8):940-9. PubMed ID: 3862732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects.
    Gnasso A; Lehner B; Haberbosch W; Leiss O; von Bergmann K; Augustin J
    Metabolism; 1986 May; 35(5):387-93. PubMed ID: 3458020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Change in composition of high density lipoprotein during gemfibrozil therapy.
    Sorisky A; Ooi TC; Simo IE; Meuffels M; Hindmarsh JT; Nair R
    Atherosclerosis; 1987 Oct; 67(2-3):181-9. PubMed ID: 3118893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutritional & pharmacologic management of hyperlipoproteinemia.
    Pickering JE
    Angiology; 1982 Sep; 33(9):577-80. PubMed ID: 6957154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenylenebis(oxy)bis[2,2-dimethylpentanoic acid]s: agents that elevate high-density lipoproteins.
    Sircar I; Hoefle M; Maxwell RE
    J Med Chem; 1983 Jul; 26(7):1020-7. PubMed ID: 6864730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
    Kesäniemi YA; Grundy SM
    JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gemfibrozil on serum lipids in man.
    Fenderson RW; Deutsch S; Menachemi E; Chin B; Samuel P
    Angiology; 1982 Sep; 33(9):581-93. PubMed ID: 6751166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia.
    Lewis JE
    Angiology; 1982 Sep; 33(9):603-12. PubMed ID: 6957156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results with gemfibrozil and background to the Helsinki Heart Study.
    Manninen V
    Am J Cardiol; 1983 Aug; 52(4):35B-38B. PubMed ID: 6351578
    [No Abstract]   [Full Text] [Related]  

  • 16. A pilot study of the effect of Gemfibrozil on some haematological parameters.
    O'Brien JR; Etherington MD; Shuttleworth RD; Adams CM; Middleton JE; Goodland FC
    Thromb Res; 1982 May; 26(4):275-9. PubMed ID: 6955993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma prekallikrein, kallikrein inhibitors, kininogen and lipids during gemfibrozil treatment in type II dyslipidaemia.
    Torstila I; Kaukola S; Manninen V; Virtamo J; Mälkönen M
    Acta Med Scand Suppl; 1982; 668():123-9. PubMed ID: 6188330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study.
    Manninen V; Mälkönen M; Eisalo A; Virtamo J; Tuomilehto J; Kuusisto P
    Acta Med Scand Suppl; 1982; 668():82-7. PubMed ID: 6762809
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.